血友病B基因治疗:1/2期101HEMB01/02研究结果
101HEMB01是一项1/2期开放标签、单臂、多中心、剂量探索研究,评估DTX101在成年男性血友病B患者中的安全性和疗效,101HEMB02为随访研究。队列1(n=3)接受1.6×10^12基因组拷贝/kg,队列2(n=3)接受5.0×10^12基因组拷贝/kg,第6周血浆FIX峰值中位数分别为7.0 IU/dL和10.0 IU/dL,均未达到20 IU/dL的目标标准;所有参与者均需补充FIX替代治疗。
要点
- DTX101两个剂量队列第6周FIX峰值中位数分别为7.0 IU/dL和10.0 IU/dL,均未达到20 IU/dL目标。
- 6名参与者中4例在101HEMB01发生治疗相关不良事件:转氨酶升高3例、疲乏1例;101HEMB02中1例发生疲乏。
- 转氨酶升高均无症状,经类固醇治疗后全部消退;DTX101项目因治疗反应不足而终止。
核心结论
- DTX101在血友病B患者中未达到20 IU/dL的FIX目标水平,所有参与者均需补充FIX替代治疗,项目因治疗反应不足而终止。
- 从该研究完成中可以汲取基因治疗临床试验设计与执行方面的经验教训,包括转基因序列和免疫抑制方案的进一步优化。
研究设计与样本
- 101HEMB01为1/2期开放标签、单臂、多中心、剂量探索研究,评估DTX101在成年男性血友病B患者中的安全性和疗效。
- 101HEMB02为随访研究,评估长期结局。
- 参与者接受DTX101 1.6×10^12基因组拷贝/kg(队列1,n=3)或5.0×10^12基因组拷贝/kg(队列2,n=3)。
- 101HEMB01中队列2监测至第44周、队列1监测至第52周,101HEMB02中额外随访4年。
主要发现
- 101HEMB01主要终点第6周血浆FIX峰值中位数:队列1为7.0 IU/dL(范围5.0-8.0),队列2为10.0 IU/dL(范围6.0-16.0)。
- FIX水平未达到20 IU/dL的目标标准,所有参与者因中间时间点FIX活性低而需要补充FIX替代治疗。
- 101HEMB01中6名参与者有4例发生治疗相关不良事件:转氨酶升高3例、疲乏1例;101HEMB02中1例发生疲乏。
- 无参与者发生相关严重不良事件;转氨酶升高均无症状,经类固醇治疗后全部消退。
关键数值与推荐
- 101HEMB01主要终点为第6周血浆FIX峰值水平,目标标准为20 IU/dL。
- 队列1(1.6×10^12基因组拷贝/kg)第6周FIX峰值中位数7.0 IU/dL(范围5.0-8.0)。
- 队列2(5.0×10^12基因组拷贝/kg)第6周FIX峰值中位数10.0 IU/dL(范围6.0-16.0)。
临床怎么用
- 原文未据此给出推荐。
局限性
- DTX101项目因治疗反应不足而终止。
- FIX水平未达到20 IU/dL的目标标准,所有参与者需要补充FIX替代治疗。
- 原文指出可从该研究完成中汲取基因治疗临床试验设计与执行的经验教训,包括转基因序列和免疫抑制方案的进一步优化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemophilia B is a rare, X-linked bleeding disorder that predominantly affects males and is caused by factor IX (FIX) gene variants, leading to spontaneous bleeding and impaired ability to clot after injury or surgeries. Standard of care is prophylaxis to increase FIX levels. DTX101 is a nonreplicating adeno-associated viral serotype rh10 gene transfer vector containing a codon-optimized wild-type human FIX coding sequence. The phase 1/2 open-label, single-arm, multicenter, dose-finding 101HEMB01 study examined the safety/efficacy of DTX101 in adult males with hemophilia B; the 101HEMB02 follow-up study assessed long-term outcomes. Participants received DTX101 as 1.6 × 1012 (cohort 1; n = 3) or 5.0 × 1012 genome copies/kg (cohort 2; n = 3) at baseline and were monitored through week 44 (cohort 2) or 52 (cohort 1) in 101HEMB01, and 4 additional years in 101HEMB02. The primary end point of 101HEMB01, peak plasma FIX level at week 6, showed median levels of 7.0 (range, 5.0-8.0) and 10.0 IU/dL (range, 6.0-16.0) in cohorts 1 and 2, respectively. Levels failed to reach the 20 IU/dL target criteria; all participants required adjunct FIX replacement therapy based on low FIX activity at intermediate time points. In 101HEMB01, 4 of 6 participants experienced treatment-related adverse events of elevated transaminase levels (n = 3) and fatigue (n = 1), and 1 experienced fatigue in 101HEMB02; none experienced related serious adverse events. Elevated transaminase levels were asymptomatic and resolved with steroids in all participants. The DTX101 program was halted for insufficient treatment response; however, from its completion, lessons can be learned regarding the design and execution of gene therapy clinical trials, including additional optimization of transgene sequence and immunosuppression protocols. The 101HEMB01 and 101HEMB02 studies were registered at www.ClinicalTrials.gov as #NCT02618915 and #NCT02971969, respectively.
引用
- Pipe S, Poma A, Rajasekhar A, et al. Gene therapy for hemophilia B: results from the phase 1/2 101HEMB01/02 studies. Blood Adv. 2025. PMID: 40197980. doi:10.1182/bloodadvances.2024015184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。